Your browser doesn't support javascript.
loading
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial.
Safran, Howard P; Winter, Kathryn; Ilson, David H; Wigle, Dennis; DiPetrillo, Thomas; Haddock, Michael G; Hong, Theodore S; Leichman, Lawrence P; Rajdev, Lakshmi; Resnick, Murray; Kachnic, Lisa A; Seaward, Samantha; Mamon, Harvey; Diaz Pardo, Dayssy Alexandra; Anderson, Carryn M; Shen, Xinglei; Sharma, Anand K; Katz, Alan W; Salo, Jonathan; Leonard, Kara L; Moughan, Jennifer; Crane, Christopher H.
Afiliación
  • Safran HP; Department of Medical Oncology, Rhode Island Hospital, Providence, RI, USA. Electronic address: hsafran@lifespan.org.
  • Winter K; NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, USA.
  • Ilson DH; Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Wigle D; Department of Thoracic Surgery, Mayo Clinic Rochester, Rochester, MN, USA.
  • DiPetrillo T; Department of Radiation Oncology, Rhode Island Hospital, Providence, RI, USA.
  • Haddock MG; Department of Radiation Oncology, Mayo Clinic Rochester, Rochester, MN, USA.
  • Hong TS; Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
  • Leichman LP; Department of Medical Oncology, UC San Diego Moores Cancer Center, New York, NY, USA.
  • Rajdev L; Department of Medical Oncology, Montefiore Medical Center-Weller Hospital-Montefiore Medical Center for Cancer Care, New York, NY, USA.
  • Resnick M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Kachnic LA; Department of Radiation Oncology, NYP/Columbia University Medical Center-Herbert Irving Comprehensive Cancer Center, New York, NY, USA.
  • Seaward S; Department of Radiation Oncology, Kaiser Permanente Oncology Clinical Trials, Oakland, CA, USA.
  • Mamon H; Department of Radiation Oncology, Brigham and Women's Hospital-Dana Farber Cancer Institute, Boston, MA, USA.
  • Diaz Pardo DA; Department of Radiation Oncology, The Ohio State University, Comprehensive Cancer Center-James Hospital and Solove Research Institute, Columbus, OH, USA.
  • Anderson CM; Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
  • Shen X; Department of Radiation Oncology, University of Kansas Cancer Center, Kansas City, KS, USA.
  • Sharma AK; Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC, USA.
  • Katz AW; Department of Radiation Oncology, University of Rochester, Rochester, NY, USA.
  • Salo J; Department of Surgical Oncology, Carolinas Medical Center, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
  • Leonard KL; Department of Radiation Oncology, Rhode Island Hospital, Providence, RI, USA.
  • Moughan J; NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, USA.
  • Crane CH; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lancet Oncol ; 23(2): 259-269, 2022 02.
Article en En | MEDLINE | ID: mdl-35038433
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 / Trastuzumab Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 / Trastuzumab Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2022 Tipo del documento: Article